Bayer, Nuvisan establish new research unit in Berlin
Waste Management Expo 2020 MAR 12&13 BIEC, Bengaluru, India

Bayer, Nuvisan to establish new research unit in Berlin

10:22 AM, 11th February 2020
Bayer logo

BERLIN, GERMANY: Bayer AG has entered into a definitive agreement to transfer a large part of its Berlin-based small molecule research unit to Nuvisan.

Nuvisan is an international service provider for clinical studies, laboratory services and contract manufacturing with several sites and clinics in Germany and France.

The strategic partnership will lay the foundation for a brand-new research entity to be established by Nuvisan in Berlin. At the same time, it will support Bayer’s increased focus on the flexibility and productivity of its R&D operating model. Financial terms were not disclosed.

The Berlin-based research unit with around 400 workplaces comprises of a fully operational team specialized in small molecule research. The research center comes with capabilities and capacities spanning the entire drug discovery value chain, including Lead Discovery, Medicinal Chemistry, Pharmacology, Drug Metabolism & Pharmacokinetics, Investigational Toxicology, and Animal Management. Bayer will retain significant research activities in Berlin, which remains the headquarters for the company’s Pharmaceuticals Division and one of its major global research sites.

Bayer and Nuvisan will cooperate closely in the coming years to build the new research center. The transaction is expected to close mid of 2020.

“With Nuvisan we have found an excellent partner with a clear plan to build up a strong full-fledged research unit in Berlin together with our dedicated team of scientists. Nuvisan shares our vision that the new research center can become an important player in research partnering based on the joint know-how and the capabilities of our highly qualified scientists,” said Dr. Joerg Moeller, Member of the Executive Committee of Bayer AG's Pharmaceuticals Division and Head of Research and Development.

“With these new drug discovery capabilities and capacities, we do not only welcome a high-performance research team, but also obtain access to excellent specialty know-how and technology. The acquisition of the research unit and its location at the Bayer R&D campus will create an operational hub in the scientific excellence cluster Berlin and allow us to significantly accelerate the drug development process from discovery to clinical trials,” added Dr. Dietrich Bruchmann, CEO and managing partner of Nuvisan.

© Worldofchemicals News



Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

Total enters Spanish solar market with two new projects

PARIS, FRANCE: Total, through its wholly owned affiliate Total Solar International, establishes its presence on the Spanish solar market through two a ...

Read more
Worley Parsons appoints new CEO

NORTH SYDNEY, AUSTRALIA: Worley Parsons Limited has appointed Chris Ashton as the Chief Executive Officer (CEO) and Managing Director, effective ...

Read more
Brenntag Food & Nutrition opens the new site in Padua, Italy

ESSEN, GERMANY: Brenntag Food & Nutrition has opened a new state-of-the-art site in Padua, Italy; a brand-new location housing operational and adm ...

Read more
Bayer, Meiogenix collaborate to advance agricultural R&D

MONHEIM, GERMANY/PARIS, FRANCE: Bayer and Meiogenix, a biotech company focused on next-generation breeding technologies, has collaborated to advance a ...

Read more
Indian scientist in Australia is close to developing coronavirus vaccine

NEW DELHI, INDIA: In a major breakthrough for global preclinical response to the novel coronavirus (nCoV) outbreak, a team led by an oversea ...

Read more
Durr revolutionizing manufacturing layout for paint shops

CHENNAI, INDIA: Growing model diversity, different drive technologies, and greater personalization are pushing conventional line manufacturing to ...

Read more uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X